Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells (Q40438301)

20 September 2017

Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells (English)

1 reference

20 September 2017

1 reference

5

Bart N Lambrecht

1 reference

20 September 2017

Joost P J J Hegmans

1

1 reference

20 September 2017

Annabrita Hemmes

series ordinal

2

1 reference

20 September 2017

Joachim G Aerts

series ordinal

3

1 reference

20 September 2017

Henk C Hoogsteden

series ordinal

4

1 reference

20 September 2017

language of work or name

English

0 references

publication date

11 March 2005

1 reference

American Journal of Respiratory and Critical Care Medicine

20 September 2017

1 reference

20 September 2017

171

1 reference

20 September 2017

10

1 reference

20 September 2017

1168-1177

1 reference

Health implications of environmental exposure to asbestos

20 September 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Surgical treatment of malignant pleural mesothelioma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

The role of surgery in diagnosis and treatment of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Multimodality treatment of diffuse malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Advances in the treatment of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Diffuse malignant pleural mesothelioma: Part I. An overview of diagnosis, staging, and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Dendritic cells and immunotherapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Dendritic cells: controllers of the immune system and a new promise for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Dendritic cell immunotherapy: mapping the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Dendritic cell maturation in active immunotherapy strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Dendritic cell biology and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

The use of dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Proteomic analysis of exosomes secreted by human mesothelioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

The dendritic cell: its potent role in the respiratory immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigen-presenting dendritic cell: influence of treatment with fluticasone propionate

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Pleural mesothelioma: little evidence, still time to do trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Clinical applications of dendritic cell vaccination in the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Mechanisms and functional significance of tumour-induced dendritic-cell defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Animal models of tumor immunity, immunotherapy and cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Establishment of a murine model of malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Interleukin-12 induces an effective antitumor response in malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

21 January 2018

CTL effector functions

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Influence of dendritic cells on tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Dendritic cell-induced activation of adaptive and innate antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Molecular identification of a danger signal that alerts the immune system to dying cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

CpG motifs in bacterial DNA and their immune effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Proteomic analysis of exosomes isolated from human malignant pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

Interleukin-7 enhances cell-mediated immune responses in vivo in an interleukin-2-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200501-057OC

10.1164/RCCM.200501-057OC

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference